Patient Site Healthcare Professional Site
VIVITROL (naltrexone for extended-release injectable suspension) VIVITROL: A Treatment Option For The Daily Struggle Against Alcohol Dependence. One dose all month long.
Healthcare Professional Site
Prescribing Information
Send to a Friend
Homepage About Vivitrol Request Information SEARCH
Request Information Graphic: Request Information
My Path to Recovery
Request a sales representative visit

Find upcoming alcoholism conferences

Updated NIAAA Guidelines

Substance Abuse Treatment Advisory
How do I start a patient on therapy?

Locate a Physician

How do I start a patient on therapy?

Request information

Thank you for your interest in VIVITROL and vivitrol.com. For more information, click on the appropriate links below.

Request a sales representative visit
Arrange to have your VIVITROL sales representative visit you.

Find upcoming alcoholism conferences
See our meetings and conferences calendar for dates and places of conferences relevant to you and VIVITROL.

Download the updated NIAAA Clinician's Guide
The updated NIAAA Clinician's Guide now includes VIVITROL as one of the medication options for treating alcohol dependence. This treatment guide has been produced by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), a component of the National Institutes of Health, with the purpose of providing tools that can help you identify patients who need help and develop treatment strategies. Since every patient is unique the guidelines can help you tailor his or her treatment to include counseling, support groups, medications including VIVITROL, or a combination of these.

Download the Substance Abuse Treatment Advisory
The US Department of Health and Human Services has released important information about VIVITROL for the treatment of alcoholism.

How do I start a patient on therapy?
To start a patient on therapy, you should enroll the patient in the VIP3 program.

  
Important Safety Information
Naltrexone has the capacity to cause hepatocellular injury when given in excessive doses. Naltrexone is contraindicated in acute hepatitis or liver failure, and its use in patients with active liver disease must be carefully considered in light of its hepatotoxic effects. The margin of separation between the apparently safe dose of naltrexone and the dose causing hepatic injury appears to be only five-fold or less. VIVITROL does not appear to be a hepatotoxin at the recommended doses. Patients should be warned of the risk of hepatic injury and advised to seek medical attention if they experience symptoms of acute hepatitis. Use of VIVITROL should be discontinued in the event of symptoms and/or signs of acute hepatitis.
VIVITROL is indicated for the treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to initiation of treatment with VIVITROL.

Patients should not be actively drinking at the time of initial VIVITROL administration.

Treatment with VIVITROL should be part of a comprehensive management program that includes psychosocial support.